Programa de Pós-Graduação em Ciências Biológicas: Fisiologia-UFRGS, Porto Alegre, Brazil.
Centro de Terapia Gênica-HCPA, Ramiro Barcelos, Porto Alegre, RS, 2350, Brazil.
Metab Brain Dis. 2018 Feb;33(1):343-345. doi: 10.1007/s11011-017-0110-5. Epub 2017 Sep 16.
Hunter syndrome (MPS II, OMIM 309900) is a lysosomal storage disorder due to deficient iduronate sulphatase activity. Patients present multiple cognitive alterations, and the aim of this work was to verify if MPS II mice also present some progressive cognitive alterations. For that, MPS II mice from 2 to 6 months of age were submitted to repeated open field and inhibitory avoidance tests to evaluate memory parameters. MPS II mice presented impaired memory at 6 months evaluated by open field test. They also performed poorly in the inhibitory avoidance test from 4 months. We conclude that MPS II mice develop cognitive alterations as the disease progresses. These tests can be used in the future to study the efficacy of therapeutic approaches in the central nervous system.
亨特综合征(MPS II,OMIM 309900)是一种溶酶体贮积症,由于缺乏艾杜糖醛酸硫酸酯酶的活性。患者表现出多种认知改变,本工作的目的是验证 MPS II 小鼠是否也存在一些进行性认知改变。为此,2 至 6 个月大的 MPS II 小鼠接受了重复的旷场和抑制性回避测试,以评估记忆参数。通过旷场试验评估,6 个月大的 MPS II 小鼠表现出记忆受损。从 4 个月起,它们在抑制性回避测试中的表现也很差。我们得出结论,MPS II 小鼠随着疾病的进展会出现认知改变。这些测试将来可用于研究中枢神经系统治疗方法的疗效。